Jazz Phar­ma­ceu­ti­cals said it sold a pri­or­i­ty re­view vouch­er to an undis­closed com­pa­ny for $200 mil­lion, land­ing the high­est price for such a vouch­er since 2016.

Jazz will take home half of the pro­ceeds, it said Tues­day in a pre­sen­ta­tion at the JP Mor­gan Health­care Con­fer­ence in San Fran­cis­co.

It re­mains un­clear who the oth­er half will go to. But the com­pa­ny ac­quired dor­daviprone, which was award­ed the rare pe­di­atric PRV, from Chimerix for $935 mil­lion in April 2025. That ac­qui­si­tion came just be­fore dor­daviprone won an ac­cel­er­at­ed ap­proval in Au­gust as the first sys­temic ther­a­py for H3 K27M-mu­tant dif­fuse glioma. Jazz al­so bought an­oth­er PRV from Spark Ther­a­peu­tics in 2018 for $110 mil­lion.

The tar­iff and trade pol­i­cy changes that made 2025 so tu­mul­tuous for phar­ma­ceu­ti­cal com­pa­nies are shap­ing up to bring ben­e­fits in the year ahead now that there's more clar­i­ty, ac­cord­ing to man­u­fac­tur­ers at the an­nu­al JP Mor­gan Health­care Con­fer­ence.

Ther­mo Fish­er and Dana­her were among com­pa­nies cit­ing po­ten­tial tail­winds for their busi­ness­es in 2026. Even so, there's no all-clear quite yet: Ther­mo Fish­er and Charles Riv­er both ex­pressed con­cerns that US gov­ern­ment re­search fund­ing cuts last year will con­tin­ue to put pres­sure on their re­search ser­vices busi­ness.

As com­pa­nies in­vest in on­shoring man­u­fac­tur­ing to the US, Ther­mo Fish­er has se­cured mul­ti­ple new con­tracts to help cus­tomers move pro­duc­tion from Eu­rope or Asia, CEO Marc Casper said Tues­day. The com­pa­ny has al­so ex­pand­ed its US foot­print in re­cent months, with Casper not­ing that the ac­qui­si­tion of Sanofi’s New Jer­sey site will pro­vide ad­di­tion­al US ca­pac­i­ty for cus­tomers.

Scribe Ther­a­peu­tics, found­ed al­most nine years ago to de­vel­op med­i­cines based on nov­el CRISPR en­zymes, is get­ting ready to test its first ther­a­py in the clin­ic this sum­mer, the gene edit­ing start­up told End­points News.

The com­pa­ny’s lead pro­gram is an epi­ge­net­ic si­lenc­ing ther­a­py de­signed to turn off genes with­out al­ter­ing the un­der­ly­ing ge­net­ic code. Scribe and com­pa­nies de­vel­op­ing sim­i­lar tech­nolo­gies have pitched the ap­proach as a po­ten­tial­ly safer al­ter­na­tive to the first wave of CRISPR ther­a­pies that make per­ma­nent changes to DNA.

Scribe’s first tar­get is the well-trod­den PC­SK9. Oth­er drug­mak­ers have shown that in­hibit­ing the gene, or the pro­tein it en­codes, leads to dras­tic re­duc­tions in low-den­si­ty lipopro­tein cho­les­terol (LDL-C), which can low­er the risk of heart dis­ease. Scribe plans to be­gin a Phase 1 clin­i­cal tri­al midyear in pa­tients with hy­per­c­ho­les­terolemia with high car­dio­vas­cu­lar risk.

Ther­mo Fish­er will be phas­ing out op­er­a­tions at its lab­o­ra­to­ry prod­ucts fac­to­ry in Asheville, NC by the end of 2026. And the ser­vice provider will be lay­ing off 421 em­ploy­ees, ac­cord­ing to a WARN no­tice.

Cer­tain prod­uct lines at the site will be trans­ferred to oth­er US fa­cil­i­ties, a Ther­mo Fish­er spokesper­son told End­points News, adding that the move does not im­pact its over­all “com­mit­ment to US man­u­fac­tur­ing.”

All im­pact­ed work­ers will re­ceive sup­port to find new em­ploy­ment, the spokesper­son said, adding, “There are times when we must evolve our or­ga­ni­za­tion to re­main in line with cur­rent cus­tomer de­mands."